Uriach increases sales by 3% in 2025 and approaches €500M in a year marked by the consolidation of its businesses
The pharmaceutical group expects inflation and the war in the Middle East to have a negative impact on this year's results
L'Hospitalet de LlobregatUriach reinforces its commitment within the natural and self-care products health segment and consolidates its business model in Europe. After a decade marked by a dozen acquisitions across the Old Continent, the Catalan pharmaceutical company closed the year 2025 with a 3% increase in sales, approaching the 500 million euros it had set as a goal when it launched its strategic plan in 2015. Although the improvement falls short of the figures recorded the previous year –revenue in 2024 increased by 54%–, the company acknowledges that the past year has been characterized by a "complex" context after several years of high-growth markets.
the figures recorded in the previous fiscal yearBeyond the slowdown in both revenue and gross operating profit, Uriach remains watchful of the effects of inflation for the upcoming fiscal year. With price escalation increasingly accentuated by the conflict in the Middle East, Segarra acknowledges that the effects of the crisis are already beginning to be felt. According to the family group's CEO, it is estimated that inflation, which has affected the purchasing power of its customers, will have a negative impact of at least one million euros on the company's sales this year. Should the war continue, the effect could be even greater, both due to the reduction in real wages and the increased cost of some raw materials used by the company.
Nevertheless, Segarra also pointed out that both the company and the natural consumer healthcare sector are "quite resilient" to the effects of the conflict. On the one hand, because sales are mainly focused on the European market, thus also avoiding the negative effects of the tariffs promoted by the President of the United States, Donald Trump. And, on the other hand, because a relevant part of the raw materials that Uriach uses for the manufacture of its products largely comes from the European continent.
Evolution of the markets
After betting on the expansion of its business in Europe, the family group closed the year with a presence in twelve European countries. The latest acquisition was precisely this 2025, when it incorporated the Greek company i-Pharma, a distributor of Uriach in the country that billed around 1.5 million euros annually.
According to the results presented this Wednesday, the improvement in sales this 2025 is mainly due to the performance of the southern European markets –Spain and Portugal– and the southwestern European markets –Italy, Romania, and Greece–, some of which are growing at rates close to double digits. On the other hand, the central and northern European markets –including Germany, France, Austria, Switzerland, and the Benelux– have registered a less positive performance.
Regarding exports, the pharmaceutical company achieved sales of 30 million euros through its three main markets, which are Germany, Spain, and France. As detailed by the group, its products are currently distributed in about eighty countries, and Latin America is the most powerful region outside of Europe. A significant portion of international sales is also concentrated in the Middle East, followed by Asia, while the United States market remains residual.
Pause in acquisitions
In the results presentation this Wednesday, Segarra assured that the group's intention for 2026 continues to be to consolidate the acquired brands and boost the company's organic growth. In this regard, he pointed out that the company intends to momentarily put acquisitions aside this year, although he does not rule out resuming operations for the next fiscal year.
In the same vein, the CEO has expressed the Uriach family's desire to continue maintaining a majority stake in the company, in which they now control around 70%. "We will continue to use debt and equity as financing formulas," indicated Segarra, who also ruled out shareholding changes or stock market listings.
Precisely on the shareholding, the group's top executive has very positively valued the entry three years ago of the British fund IGC, which today controls about 30% of the shares. "We believe it is the ideal travel companion for us, because it understands the dynamics of a family business and consolidation. [...] We are very happy and the idea is to continue like this," Segarra summarized.